Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00 after delivering 20% EPS growth in its first quarter. The pharmaceutical distributor generated $15 billion in Q1 revenues driven by oncology services, specialty distribution, and GLP-1 therapies.

The guidance lift follows strong execution in high-margin specialty segments. Oncology and GLP-1 weight-loss drugs—an increasingly lucrative distribution opportunity—are offsetting pressure in MCK's core business. The company faces headwinds from branded drug price declines and generic conversion dynamics that typically compress distributor margins.

Regulatory risk looms. Potential reforms to the 340B drug discount program and Medicare Part D changes under the Inflation Reduction Act could reshape reimbursement economics for distributors. MCK has not quantified the impact of these policy uncertainties on forward earnings.

The raised guidance suggests management confidence that specialty growth can absorb traditional wholesale margin pressure through at least the end of fiscal 2027.